About Us: Leadership

Chief Executive Officer 

Brian McVeigh is the Chairman, Chief Executive Officer, and Co-Founder of Code Bio. He also serves as the Chairman of the Board of Genisphere, LLC, a Board Observer of Araris Biotech AG, and is a Venture Partner with 4BIO Capital. He has held leadership roles in both private and public biotechs, including a 25-year career with GlaxoSmithKline (GSK) Pharmaceuticals where he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management. Brian holds Bachelor of Science degrees in Accounting and Finance from LaSalle University, an MBA with a Concentration in Finance from Villanova University, a Post MBA Certificate in Pharmaceutical Marketing from Saint Joseph's University, and a Certificate of Professional Development from the Wharton Business School at the University of Pennsylvania. He is a Certified Public Accountant, Certified Management Accountant, and Certified Licensing Professional.

Chief Scientific Officer 

Dave Anderson serves as Code Bio’s Chief Scientific Officer. He is responsible for guiding the long-term vision for research and discovery and for driving Code Bio’s overall scientific strategy in Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases. Dave leads efforts across research, discovery, translational medicine, regulatory strategy, and early development.

Prior to joining Code Bio, Dave served as Senior Vice President, Research at SwanBio Therapeutics directing translation of genetic therapies in development for the treatment of rare neurological diseases of the spinal cord. Prior to his role at SwanBio, Dave directed all preclinical research for the treatment of neurological diseases at Spark Therapeutics, Inc., where he oversaw development and growth of the central nervous system portfolio and team during his tenure.

​

Beyond his experience with SwanBio and Spark, Dave also co-founded two early-stage biotechnology companies, and previously served as faculty at Thomas Jefferson University. His expertise includes all aspects of experimental design and management with significant experience in molecular discovery and translation of basic research into preclinical animal models to support drug development.

Dave received a PhD in Molecular and Cell Biology from Thomas Jefferson University in 2005 and a B.Sc./Hons in Biomedical Sciences from Sheffield Hallam University in 1996.

Chief Platform Technologies Officer

Bob Getts serves as Chief Platform Technologies Officer and is a Co-Founder of Code Bio. Bob leads all of the company’s discovery, platform development and novel application activities. He also serves as a Scientific Advisor for AllerGenis LLC; as a member of the Rowan University Biomedical Engineering Industrial and Medical Advisory Board; as an Associate Clinical Preceptor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy; and as a graduate program advisor at Thomas Jefferson University and The University of Maryland.

​

Bob possesses more than 25 years of experience using nanotechnologies as tools to develop life science reagents, kits, and diagnostic assays. Most recently he served as the Chief Scientific Officer and acting CEO at Genisphere, LLC. where he led the development of 3DNA as a novel non-viral targeted delivery platform for the delivery of multiple types of therapeutic cargo including small drugs, siRNA, biologics, and whole genes.

​

Bob has a Ph.D. in Biochemistry from Lehigh University, has over 40 peer-review publications, abstracts, and presentations, and is listed as an inventor on more than 20 issued patents and over 35 U.S. and international patent applications.

Chief Technical Officer

Alex oversees the overall manufacturing strategy, technical development and chemistry, manufacturing, and controls (CMC) roadmap at Code Bio.

​

Alex has more than 20 years of experience in the biotech and pharmaceutical industry. Prior to Code, he served as Chief Technical Officer at BridgeBio Gene Therapy. During his time at BridgeBio, Alex developed the regulatory CMC strategy, led process and analytical development as well as external manufacturing for several clinical-stage AAV gene therapy programs. Alex also held the role of Chief Technical Officer at Istari Oncology, where he successfully negotiated Phase III comparability and control strategies with the FDA for the company’s glioblastoma monotherapy program. Dr. Tracy also served as Vice President of Pharmaceutical Development and Manufacturing at Enzyvant/Roivant Sciences, Head of Manufacturing Science & Technology at Hospira, a Pfizer Company, as well as Global Head of Manufacturing Science & Technology at Novartis Vaccines & Diagnostics.

​

Alex received a PhD in Biochemistry and Molecular Biology from University of Georgia, an M.S. in Chemistry at George Mason University, as well as a B.S. in Chemistry and English from The College of William and Mary. 

Head of Process Development and Preclinical Production

Lori Getts is the Head of Process Development and Preclinical Production, and a Co-Founder of Code Bio. Lori leads the process scale up, CMC, and preclinical development functions for all of our pipeline programs. She has 20+ years’ experience in the biotech industry, developing therapeutic drug delivery platforms for targeted therapeutics, as well as developing and commercializing reagents and research kits used in a variety of biological assays throughout the life sciences and diagnostic sectors. 

​

Lori was most recently the Vice President of Preclinical and Process Development at Genisphere, LLC where she played a pivotal role in the development of the 3DNA platform. She also directed the manufacture and QC of Genisphere’s entire reagents and research kit product line (over 135 products) including the OEM manufacture of the company’s flagship product, FlashTag®.

​

Lori is a co-author of many posters and papers as well as a co-inventor on several of the company’s patents and patent applications. She received her Ph.D. in Chemistry (Biochemistry focus) from Lehigh University and completed her Ph.D. thesis at Fox Chase Cancer Center where she used ovarian cancer model systems to study ovarian cancer etiology.

Head of Analytical Methods Development, Chemistry, Manufacturing, and Controls (CMC)

Matt Roberts is Code Bio’s Head of Analytical Methods Development, CMC. Matt’s focus is on building a state-of-the-art team responsible for developing fit-for-purpose analytical methods for characterization, in-process, stability, and Quality Control (QC) release testing of Code Bio’s innovative gene delivery technology and product pipeline.

Matt has more than 10 years of experience in the pharmaceutical industry. He started his industry career at GlaxoSmithKline as an R&D Biopharmaceutical Technical Development Program Associate (now the Future Leaders Program). Matt’s responsibilities in subsequent roles at GSK spanned analytical methods development for the assessment of biopharmaceutical and cell and gene therapies, leading teams of assay developers, and establishing analytical testing strategies for assets ranging from candidate selection to launched product. Prior to joining Code, Matt served as GSK’s Director of Cell & Gene Therapy Analytical Development, where he managed a team of US- and UK-based group leaders to develop, transfer, and validate analytical methods in support of GSK’s product pipeline.

​

Matt holds a PhD and MPhil in Molecular Biophysics and Biochemistry from Yale University and a Bachelor of Science degree in Biochemistry from the University of Delaware.

Head of Translational Medicine

Latha Vasireddy serves as Code Bio’s Head of Translational Medicine. She leads the translational development team to identify novel therapeutic strategies for delivering genetic payloads in multiple rare disease programs. 

Latha has more than 12 years of experience in developing AAV-mediated gene therapy candidates for rare neurodegenerative diseases. Prior to joining Code Bio, she worked as a Director of Translational Toxicology at SwanBio Therapeutics and directed AAV-mediated gene therapies in neurological diseases of the spinal cord. At SwanBio, Latha led the organization’s lead candidate from the earliest preclinical stage through IND. Previously, Latha served as a Director of Translational Sciences at the Center for Advanced Retinal & Ocular Therapeutics (CAROT) at the University of Pennsylvania where she was involved in the clinical development of multiple gene therapy products for retinal degenerative disease. 

Latha received a Ph.D. in Biochemistry from Osmania University, India, and trained in molecular mechanisms of retinal degenerative diseases during her post-doctoral fellowship at the Kellogg Eye Center at the University of Michigan. She also earned her Certificate in Translational Sciences and Regulatory Affairs from the University of Pennsylvania.